Skip to main content

The Value of Genetic and Genomic Technologies Workshop Summary (2010) / Chapter Skim
Currently Skimming:

5 Closing Remarks
Pages 49-54

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 49...
... Burke called upon the case scenario presenters and the participants to share their thoughts on take-home messages of the day and to offer questions for further consideration by the roundtable. RESEARCH SySTEMS A participant noted that one recurring theme was the absence of a suitable research infrastructure for obtaining the necessary data needed to answer some of the questions raised.
Read the entire page →
From page 50...
... " that was raised relative to Lynch syndrome testing, and he asked it of pharmacogenomic testing for warfarin dosing. There is already enough evidence, he said, to conclude that there is no major benefit from genomic testing versus current modes of coagulation management in well-managed clinics.
Read the entire page →
From page 51...
... Wicklund said that, because she was coming from a pre-natal clinical setting, she expected that there will be companies offering panels of over one hundred different single gene tests to determine carrier status. The cost might be less for a panel of 100 than for a single genetic test for cystic fibrosis or spinal muscular atrophy.
Read the entire page →
From page 52...
... This would be a body focused on overarching strategy and coordination, somewhat similar to the HMO Research Network, so that it would not lead to an excess of parallel activity but rather a synergy of efforts. Burke responded that the emerging Genomics Applications in Practice and Prevention Network (GAPPNet)
Read the entire page →
From page 53...
... These are issues that could be explored using the convening function of the roundtable, Burke suggested. As was noted during the workshop, many of these challenges are not exclusive to genetics, but rather are core issues for health care as a whole (e.g., effectiveness versus efficacy data, building efficient research infrastructures, and randomized controlled trials versus other types of evidence)
Read the entire page →

Key Terms

  • genomic information
  • genomic tests
  • genomic testing
  • versus personal
  • genomic profiling

  • clinical setting
  • health outcome
  • marc williams
  • lynch syndrome
  • screening model

  • personal utility
  • established analytic
  • bruce blumberg
  • challenges involved
  • personal health

  • healthcare setting
  • cogenomic testing
  • participant noted
  • common aspects
  • consider clinical

  • single gene
  • utility clinical
  • people choose
  • emerging genomics
  • planning facility

  • participants look
  • controlled trials
  • roundtable activities
  • individual patient
  • considering clinical


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.